Medical Areas of Focus and Product Pipeline

Abogen is committed to applying mRNA technology and its proprietary LNP platform to develop high quality innovative products to address unmet medical needs. Our product development is focused on four areas — infectious disease, tumor immunotherapy, tumor vaccine, and protein replacement.

  • Prophylactic Vaccines
  • Immuno-oncology Modulators
  • Cancer Vaccines
  • Protein Replacements
Infectious Diseases

Since late 2019, the notorious COVID-19 outbreak has been a loud warning that infectious diseases are not only threats to human health as well as to the global economy and social stability. In addition to the COVID-19 virus, other types of viruses, such as the monkeypox virus and the seasonal influenza virus are also causing serious threats to human. These pandemic and endemic outbreaks demand the development of high quality vaccines and drugs.

mRNA vaccine, once delivered into cells by a delivery system such as LNP, will express vaccine target antigens within cells. The expressed antigens will in turn induce B cell and T cell immune responses to provide protective immunity against future infection. The quick and simple manufacturing process of mRNA vaccine ensures a quick response using this platform to a sudden outbreak like COVID-19. Currently, a large population of the world has received the COVID-19 mRNA vaccination, demonstrating the key role of mRNA vaccines in protecting human life.

In early 2020, Abogen, in collaboration with the Chinese Academy of Military Medical Sciences and Walvax Biotechnology, started the campaign to develop a COVID-19 vaccine, ARCoV, against the original strain. Along with the appearance of COVID-19 virus variants, Abogen continues to develop monovalent or multi-valent mRNA vaccines against COVID-19 variants, including Omicron variants. In addition, we are also committed to developing a broader spectrum of vaccines against other infectious viruses which bring challenges to human health and life.


Malignant tumors pose a major threat to people's life and health. Currently, It is estimated that 20 million new cases and 10 million deaths of malignant patients occur each year worldwide. Global cancer cases are expected to increase by 47% by 2040. With an aging population, the incidence of cancer in China is rising year by year, and its mortality rate ranks among the top in the world. There is a huge unmet medical need in the field of malignant tumors. Under the plan known of Healthy China 2030, "the five-year overall survival rate of cancers shall be increased by 15%". 

mRNA drugs can treat tumors by either stimulating a strong and specific immune response or expressing targeted proteins effectively. Thus, multiple immune-oncology treatments can be achieved, including activation of T cells with specific tumor antigen, relief of tumor immunosuppression, and improvement of tumor immune microenvironment. At the same time, mRNA technology can solve an array of challenges facing traditional cancer drug development, bring new ideas for tumor immunotherapy, and overcome the obstacle of "undruggable" drug targets.

Abogen is committed to applying the mRNA platform technology to explore innovative immuno-oncology modalities, and thereby bring hope to patients.